Прогностическое значение амплификации 1q21 при множественной миеломе
- Авторы: Абрамова ТВ1, Обухова ТН1, Менделеева ЛП1, Покровская ОС1, Грибанова ЕО1, Рыжко ВВ1, Гребенюк ЛА1, Нарейко МВ1, Соловьев МВ1, Вотякова ОМ2, Куликов СМ1, Русинов МА1, Савченко ВГ1
-
Учреждения:
- ФГБУ «Гематологический научный центр» Минздрава России
- ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Минздрава России
- Выпуск: Том 89, № 7 (2017)
- Страницы: 32-38
- Раздел: Передовая статья
- URL: https://journal-vniispk.ru/0040-3660/article/view/32260
- DOI: https://doi.org/10.17116/terarkh201789732-38
- ID: 32260
Цитировать
Полный текст
Аннотация
Полный текст
Открыть статью на сайте журналаОб авторах
Т В Абрамова
ФГБУ «Гематологический научный центр» Минздрава РоссииМосква, Россия
Т Н Обухова
ФГБУ «Гематологический научный центр» Минздрава РоссииМосква, Россия
Л П Менделеева
ФГБУ «Гематологический научный центр» Минздрава РоссииМосква, Россия
О С Покровская
ФГБУ «Гематологический научный центр» Минздрава РоссииМосква, Россия
Е О Грибанова
ФГБУ «Гематологический научный центр» Минздрава РоссииМосква, Россия
В В Рыжко
ФГБУ «Гематологический научный центр» Минздрава РоссииМосква, Россия
Л А Гребенюк
ФГБУ «Гематологический научный центр» Минздрава РоссииМосква, Россия
М В Нарейко
ФГБУ «Гематологический научный центр» Минздрава РоссииМосква, Россия
М В Соловьев
ФГБУ «Гематологический научный центр» Минздрава РоссииМосква, Россия
О М Вотякова
ФГБУ «Российский онкологический научный центр им. Н.Н. Блохина» Минздрава РоссииМосква, Россия
С М Куликов
ФГБУ «Гематологический научный центр» Минздрава РоссииМосква, Россия
М А Русинов
ФГБУ «Гематологический научный центр» Минздрава РоссииМосква, Россия
В Г Савченко
ФГБУ «Гематологический научный центр» Минздрава РоссииМосква, Россия
Список литературы
- Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008.
- Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood. 2011; 117(19):5019-5032. https://doi.org/10.1182/blood-2011-01-293050
- Nemec P, Zemanova Z, Greslikova H, Greslikova H, Michalova K, Filkova H, Tajtlova J, Kralova D, Kupska R, Smetana J, Krejci M, Pour L, Zahradova L, Sandecka V, Adam Z, Buchler T, Spicka I, Gregora E, Kuglik P, Hajek R. Gain of 1q21 Is an Unfavorable Genetic Prognostic Factor for Multiple Myeloma Patients Treated with High-Dose Chemotherapy. Biol Blood Marrow Transplant. 2010;16(4):548-554. https://doi.org/10.1016/j.bbmt.2009.11.025
- Kuehl WM, Bergsagel PF. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest. 2012;122(10):3456-3463. https://doi.org/10.1172/jci61188
- Mahindra A, Laubach J, Raje N, Munshi N, Richardson PG, Anderson K. Latest advanced and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol. 2012;9(3):135-143. https://doi.org/10.1038/nrclinonc.2012.15
- Hervé AL, Florence M, Philippe M, Michel A, Thierry F, Kenneth A, Jean-Luc H, Nikhil M, Stéphane M. Molecular heterogeneity of multiple myeloma: pathogenesis, prognosis, and therapeutic implications. J Clin Oncol. 2011;29(14):1893-1897. https://doi.org/10.1200/jco.2010.32.8435
- Fonseca R, Debes-Marun CS, Picken EB, Dewald GW, Bryant SC, Winkler JM, Blood E, Oken MM, Santana-Dávila R, González-Paz N, Kyle RA, Gertz MA, Dispenzieri A, Lacy MQ, Greipp PR. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood. 2003;102(7):2562-2567. https://doi.org/10.1182/blood-2003-02-0493
- Morgan GJ, Walker BA and Davies FE. The genetic architecture of multiple myeloma. Nature Reviews Cancer. 2012;12(5):335-348. https://doi.org/10.1038/nrc3257
- Avet-Loiseau H, Leleu X, Roussel M, Moreau P, Guerin-Charbonnel C, Caillot D, Marit G, Benboubker L, Voillat L, Mathiot C, Kolb B, Macro M, Campion L, Wetterwald M, Stoppa AM, Hulin C, Facon T, Attal M, Minvielle S, Harousseau JL. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol. 2010;28(30):4630-4634. https://doi.org/10.1200/jco.2010.28.3945
- Bergsagel PL, Kuehl WM. Chromosome translocations in multiple myeloma. Oncogene. 2001;20(40):5611-5622. https://doi.org/10.1038/sj.onc.1204641
- DeWald GW, Kyle RA, Hicks GA, Greipp PR. The clinical significance of cytogenetic studies in 100 patients with multiple myeloma, plasma cell leukemia, or amyloidosis. Blood. 1985;66(2):380-390.
- Kumar S, Fonseca R, Ketterling RP, Dispenzieri A, Lacy MQ, Gertz MA, Hayman SR, Buadi FK, Dingli D, Knudson RA, Greenberg A, Russell SJ, Zeldenrust SR, Lust JA, Kyle RA, Bergsagel L, Rajkumar SV. Trisomies in multiple myeloma: Impact on survival in patients with high-risk cytogenetics. Blood. 2012;119(9):2100-2105. https://doi.org/10.1182/blood-2011-11-390658
- Nahi H, Sutlu T, Jansson M, Alici E, Gahrton G. Clinical impact of chromosomal aberrations in multiple myeloma. J Intern Med. 2010;269(2):137-147. https://doi.org/10.1111/j.1365-2796.2010.02324.x
- Ni IB, Ching NC, Meng CK, Zakaria Z. Translocation t(11;14) (q13;q32) and genomic imbalances in multi-ethnic multiple myeloma patients: a Malaysian study. Hematol Rep. 2012;4(3):e19. https://doi.org/10.4081/hr.2012.e19
- Segges P, Braggio E. Genetic Markers Used for Risk Stratification in Multiple Myeloma. Genet Res Int. 2011;2011:798089. https://doi.org/10.4061/2011/798089
- Ross FM, Chiecchio L, Dagrada G, Protheroe Rebecca K.M, Stockley DM, Harrison CJ, Cross Nicholas CP, Szubert AJ, Drayson MT, and Morgan GJ. The t(14;20) is a poor prognostic factor in myeloma but is associated with long term stable disease in MGUS. Haematologica. 2010;95(7):1221-1225. https://doi.org/10.3324/haematol.2009.016329
- Avet-Loiseau H, Attal M, Campion L, Caillot D, Hulin C, Marit G, Stoppa AM, Voillat L, Wetterwald M, Pegourie B, Voog E, Tiab M, Banos A, Jaubert J, Bouscary D, Macro M, Kolb B, Traulle C, Mathiot C, Magrangeas F, Minvielle S, Facon T, Moreau P. Longterm analysis of the IFM 99 trials for myeloma: Cytogenetic abnormalities [(t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol. 2012;30(16):1949-1952. https://doi.org/10.1200/jco.2011.36.5726
- Mikhael JR, Dingli D, Roy V, Reeder CB, Buadi FK, Hayman SR, Dispenzieri A, Fonseca R, Sher T, Kyle RA, Lin Y, Russell SJ, Kumar S, Bergsagel PL, Zeldenrust SR, Leung N, Drake MT, Kapoor P, Ansell SM, Witzig TE, Lust JA, Dalton RJ, Gertz MA, Stewart AK, Rajkumar SV, Chanan-Khan A, Lacy MQ. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013;88(4):360-376. https://doi.org/10.1016/j.mayocp.2013.01.019
- Avet-Louseau H, Daviet A, Sauner S, Bataille R. Intergroupe Francophone du Myélome. Chromosome 13 abnormalities in multiple myeloma are mostly monosomy 13. Br J Haematol. 2000;111(4):1116-1117. https://doi.org/10.1046/j.1365-2141.2000.02488.x
- Sawyer JR. The prognostic significance of cytogenetics and molecular profiling in multiple myeloma. Cancer Genet. 2011;204(1):3-12. https://doi.org/10.1016/j.cancergencyto.2010.11.002
- Morgan GJ, Gregory WM, Davies FE, Bell SE, Szubert AJ, Brown JM, Coy NN, Cook G, Russell NH, Rudin C, Roddie H, Drayson MT, Owen RG, Ross FM, Jackson GH, Child JA; National Cancer Research Institute Haematological Oncology Clinical Studies Group. The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood. 2012;119(1):7-15. https://doi.org/10.1182/blood-2011-06-357038
- An G, Xu Y, Shi L, Zhong S, Deng S, Xie Z, Sui W, Zhan F, and Qiu L. Chromosome 1q21 gains confer inferior outcomes in multiple myeloma treated with bortezomib but copy number variation and percentage of plasma cells involved have no prognostic value. Haematologica. 2013;99(2):353-359. https://doi.org/10.3324/haematol.2013.088211
- Neben K, Lokhorst HM, Jauch A, Bertsch U, Hielscher T, Van der Holt B, Salwender H, Blau IW, Weisel K, Pfreundschuh M, Scheid C, Dührsen U, Lindemann W, Schmidt-Wolf IG, Peter N, Teschendorf C, Martin H, Haenel M, Derigs HG, Raab MS, Ho AD, van de Velde H, Hose D, Sonneveld P, Goldschmidt H. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p. Blood. 2012;119(4):940-948. https://doi.org/10.1182/blood-2011-09-379164
- Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, LeLeu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-e548. https://doi.org/10.1016/s1470-2045(14)70442-5
- Miltenyi Biotec. Accessed March 1, 2016. Available at: http://www.miltenyibiotec.com
- Simons A, Shaffer LG, Hastings RJ. Cytogenetic Nomenclature: Changes in the ISCN 2013 Compared to the 2009 Edition. Cytogenet Genome Res. 2013;141:1-6. https://doi.org/10.1159/000353118
- Sawyer JR, Waldron JA, Jagannath S, Barlogie B. Cytogenetic findings in 200 patients with multiple myeloma. Cancer Genet Cytogenet. 1995;82(1):41-49. https://doi.org/10.1016/0165-4608(94)00284-i
- Stewart AK, Fonseca R. Prognostic and therapeutic significance of myeloma genetics and gene expression profiling. J Clin Oncol. 2005;23(26):6339-6344. https://doi.org/10.1200/jco.2005.05.023
- Zhan F, Colla S, Wu X, Chen B, Stewart JP, Kuehl WM, Barlogie B, Shaughnessy JD. CKS1B, overexpressed in aggressive disease, regulates multiple myeloma growth and survival through SKP2- and p27Kip1-dependent and -independent mechanisms. Blood. 2007;109(11):4995-5001. https://doi.org/10.1182/blood-2006-07-038703
- Bahmanyar M, Qi X, Chang H. Genomic aberrations in anaplastic multiple myeloma: High frequency of 1q21(CKS1B) amplifications. Leuk Res. 2013;37(12):1726-1728. https://doi.org/10.1016/j.leukres.2013.09.025
- Zhang Y. CKS1B (CDC28 protein kinase regulatory subunit 1B). Atlas Genet Cytogenet Oncol Haematol. 2011;14(7):676-678. https://doi.org/10.4267/2042/44803
- Chang H, Jiang N, Jiang H, Saha MN, Qi C, Xu W, Reece D. CKS1B nuclear expression is inversely correlated with p27Kip1 expression and is predictive of an adverse survival in patients with multiple myeloma. Haematologica. 2010;95(9):1542-1547. https://doi.org/10.3324/haematol.2009.022210
- Denicourt C, Saenz CC, Datnow B, Cui Xian-Shu, Dowdy SF. Relocalized p27Kip1 Tumor Suppressor Functions as a Cytoplasmic Metastatic Oncogene in Melanoma. Cancer Res. 2007;67(19):9238-9243. https://doi.org/10.1158/0008-5472.can-07-1375
- Shaughnessy J. Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma. Hematology. 2005;10(Suppl.1):117-126. https://doi.org/10.1080/10245330512331390140
- Chen M-H, Qi C, Reece D, Chang H. Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib. Hum Pathol. 2012;43(6):858-864. https://doi.org/10.1016/j.humpath.2011.07.013
- Fonseca R, Van Wier SA, Chng WJ, Lacy MQ, Dispenzieri A, Bergsagel PL, Rajkumar SV, Greipp PR, Litzow MR, Price-Troska T, Henderson KJ, Ahmann GJ, Gertz MA. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia. 2006; 20(11):2034-2040. https://doi.org/10.1038/sj.leu.2404403
- Yu W, Guo R, Qu X, Qiu H, Li J, Zhang R, Chen L. The amplification of 1q21 is an adverse prognostic factor in patients with multiple myeloma in a Chinese population. Onco Targets Ther. 2016;9:295-302. https://doi.org/10.2147/ott.s95381
Дополнительные файлы
